Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.371
-0.002 (-0.62%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cyclacel Pharmaceuticals Stock Forecast
CYCC's stock price has decreased by -91.81% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CYCC stock has a target of 11, which predicts an increase of 2,862.56% from the current stock price of 0.37.
Analyst Consensus: Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
The average analyst rating for CYCC stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $21 → $11 | Strong Buy | Maintains | $21 → $11 | +2,862.56% | May 3, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $16 → $21 | Strong Buy | Maintains | $16 → $21 | +5,555.80% | Dec 19, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $120 | Buy | Maintains | $120 | +32,218.88% | May 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $150 → $120 | Buy | Maintains | $150 → $120 | +32,218.88% | Mar 7, 2023 |
Financial Forecast
Revenue This Year
43.86K
from 420.00K
Decreased by -89.56%
Revenue Next Year
51.00K
from 43.86K
Increased by 16.28%
EPS This Year
-3.19
from -26.75
EPS Next Year
-2.03
from -3.19
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 55,650 | 105,000 | 105,000 | ||
| Avg | 43,860 | 51,000 | 102,000 | ||
| Low | 32,340 | n/a | 98,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -86.8% | 139.4% | 105.9% | ||
| Avg | -89.6% | 16.3% | 100.0% | ||
| Low | -92.3% | - | 92.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.40 | -1.64 | -1.67 | ||
| Avg | -3.19 | -2.03 | -1.62 | ||
| Low | -3.89 | -2.37 | -1.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.